Search research articles
Contact Us
Filters
Showing results (101-110 of 215) with videos related to
Page
of 22
Sort By:
Anti-Cancer Drugs
|
March 14, 2003
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis
Walter J Loos, Hans Gelderblom, Jaap Verweij, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
July 9, 2013
The issue of non-specific binding of cabazitaxel
Peter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Walter J Loos, et al.
British Journal of Cancer
|
July 4, 1998
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line
J Ma, M Maliepaard, K Nooter, et al.
Anti-Cancer Drugs
|
November 26, 1999
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans
W J Loos, J Verweij, H J Gelderblom, et al.
Clinical Pharmacology and Therapeutics
|
October 31, 2003
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches
Albert J Ten Tije, Walter J Loos, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 1998
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
A Sparreboom, M J de Jonge, C J Punt, et al.
Cancer Biology & Therapy
|
May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecan
Alex Sparreboom, Walter J Loos, Herman Burger, et al.
Cancer Chemotherapy and Pharmacology
|
December 20, 2008
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
Inge R H M Konings, Frederike K Engels, Stefan Sleijfer, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 26, 2009
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn, Stefan Sleijfer, Mei-Ho Lam, et al.
Clinical Pharmacology and Therapeutics
|
December 14, 2004
Mechanism-based models for topotecan-induced neutropenia
Frédéric Léger, Walter J Loos, Roland Bugat, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 215) with videos related to
Sort By:
Page
of 22
Anti-Cancer Drugs
|
March 14, 2003
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis
Walter J Loos, Hans Gelderblom, Jaap Verweij, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
July 9, 2013
The issue of non-specific binding of cabazitaxel
Peter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Walter J Loos, et al.
British Journal of Cancer
|
July 4, 1998
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line
J Ma, M Maliepaard, K Nooter, et al.
Anti-Cancer Drugs
|
November 26, 1999
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans
W J Loos, J Verweij, H J Gelderblom, et al.
Clinical Pharmacology and Therapeutics
|
October 31, 2003
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches
Albert J Ten Tije, Walter J Loos, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 1998
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
A Sparreboom, M J de Jonge, C J Punt, et al.
Cancer Biology & Therapy
|
May 24, 2005
Effect of ABCG2 genotype on the oral bioavailability of topotecan
Alex Sparreboom, Walter J Loos, Herman Burger, et al.
Cancer Chemotherapy and Pharmacology
|
December 20, 2008
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
Inge R H M Konings, Frederike K Engels, Stefan Sleijfer, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 26, 2009
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn, Stefan Sleijfer, Mei-Ho Lam, et al.
Clinical Pharmacology and Therapeutics
|
December 14, 2004
Mechanism-based models for topotecan-induced neutropenia
Frédéric Léger, Walter J Loos, Roland Bugat, et al.
Page
of 22